Published on June 5, 2012 at 1:41 AM
"Significant treatment progress has been achieved for patients with
advanced melanoma, particularly those with BRAF mutations, over the past
few years," said Paolo A. Ascierto, MD, Director of the Unit of Medical
Oncology and Innovative Therapy, National Tumor Institute Fondazione G.
Pascale. "However, for patients with NRAS mutations, no targeted
treatment has been available and prognosis is poor. MEK162 has shown for
the first time efficacy in the NRAS mutated melanoma population. This is
another important brick in the wall we are building to stop melanoma."
In conclusion, MEK162, the first targeted therapy to show activity in
patients with NRAS mutant melanoma, showed clinical activity and good
tolerability in patients with BRAF and NRAS mutated advanced melanoma.
Novartis is evaluating the development options of MEK162 in melanoma.
Source: Array BioPharma